People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies, insulin administration is manually controlled, while hybrid ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...

Senseonics Holdings has filed for CE Mark registration for the Eversense 365 CGM system, paving the way for commercialization in European Union countries by Acensia Diabetes Care.

Advanced sensing features are coming to wearables beginning in 2025 and Penn State’s device, made with laser-modified ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With ...